Pharmacological approaches using escitalopram and other SSRIs were found to reduce (IL)-6 levels and TNF-α levels in patients remitted from depression, and it is quite interesting to note that low levels of IL-1β and leptin levels predicted remission in association with SSRI treatment [79] in addition to improving the aberrant HPA dysfunction to baseline activity [80]. This evidence concerns the gene TNF and major depressive disorder.